Physician profile
Guy R Crowder
NPI 1386031011
$952.15
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $604 · 2020: $223 · 2021: $125.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $191.47 | 2019-2020 | |
| Novo Nordisk INC | $174.14 | 2019-2021 | |
| Amgen INC. | $129.01 | 2019 | |
| Lilly USA, LLC | $64.65 | 2019-2020 | |
| Astellas Pharma US INC | $54.14 | 2019-2020 | |
| Glaxosmithkline, LLC. | $51.88 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $42.18 | 2019 | |
| Avanir Pharmaceuticals, INC. | $32.42 | 2019 | |
| Pfizer INC. | $30.54 | 2019 | |
| Allergan, INC. | $28.12 | 2019-2020 | |
| Amarin Pharma, INC. | $25.72 | 2020 | |
| Merck Sharp & Dohme LLC | $23.54 | 2019-2020 | |
| Sanofi Pasteur INC. | $18.14 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.68 | 2019 | |
| Abbvie INC. | $17.17 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $14.59 | 2019 | |
| Edwards Lifesciences Corporation | $12.73 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.63 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.40 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guy Crowder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.